InspireMD enrolls first patient in CGUARDIANS II pivotal TCAR study for CGuard Prime

InspireMD, Inc.

First patient enrolled by Dr. Patrick Muck at Good Samaritan Hospital (TriHealth, Cincinnati).
Prospective, single-arm study: 50+ evaluable patients; acute device/technical success endpoints.
CEO targets FDA approval for CGuard Prime CAS indication in H1 2025; TCAR market ~30,000 procedures/year.
Over 60,000 CGuard devices sold globally; MicroNet mesh cited for protective outcomes.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.